US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
Executive Summary
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
You may also be interested in...
Protecting Rx Manufacturing From COVID: US FDA Offers Directions For Firms
Guidance provides agency’s expectations for keeping virus out of drugs and facilities by protecting, monitoring, and excluding workers.
FDA Warns Against Using Compounded Remdesivir Due To Quality Concerns
Although compounding of certain shortage drugs is allowed during the public health emergency, remdesivir is off limits due to its complexity. Providers should only use the FDA-approved version of the drug, Gilead’s Veklury, the agency says.
US FDA Gives Industry An Extension On Nitrosamine Risk Assessments
Drug makers win one-month reprieve for their nitrosamine risk assessments for new drug products and approved products.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: